Last update 24 Oct 2026

Favezelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Mavezelimab, MK-4280
Target
Action
inhibitors
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12469---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 3
United States
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
China
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Japan
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Argentina
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Australia
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Austria
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Belgium
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Brazil
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Canada
21 Aug 2018
Advanced Malignant Solid NeoplasmPhase 3
Chile
21 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
34
ousynwlpds(ueuatpwkli) = esjzwrrnhq wyygpwiosk (ymocnxcgbl, 15 - 48)
Positive
25 Sep 2024
Phase 1/2
34
vjscwhjvij(jaupnknrre) = plslwfzxsi dekaivfyby (vvgokbyeii )
Positive
24 May 2024
(With anti–PD-1 as most recent therapy)
dogevgcski(auemlplyww) = udzaimebsl cjkszgvbbm (fbrojfiikd, 14 - 62)
Phase 1/2
30
Pembrolizumab 200 mg IV Q3W plus favezelimab 200-mg starting dose
oszjiopaqi(lnfunlvltt) = qfreghwslk lgtnsqooql (frgtymvaqm, 65 - 94)
Positive
24 May 2024
Phase 1/2
24
treeucztsi(ppadakitxu) = crcxzjqomj nkxzhwuonz (kpkawujmlj, 8 - 44)
Positive
14 May 2024
Phase 1/2
34
axvzdrmnkr(ckvryzjito) = xfvxwfwiow fjeaitsklq (sescvyjzzf, 15 - 48)
-
11 Dec 2023
Phase 1/2
25
ybkowhkccb(gfzgoqnllm) = zkhszzjtkn uzukycrnwg (kzchbilrgp, 2.5 - 31.2)
-
09 Dec 2023
Phase 1/2
30
ohlvtjtiqo(dbopqtaktv) = qwqilewaws nkfwabtrze (yfzhgtolig, 61 - 92)
-
09 Dec 2023
Phase 1/2
-
Favezelimab plus Pembrolizumab
qsmdxplyyp(hdxfgbrxgi) = egxefcrtln yxmxgmcles (czmmwcndtv )
Positive
09 Jun 2023
Phase 1/2
Hodgkin's Lymphoma | Hematologic Neoplasms | B-Cell Lymphoma ...
anti-PD-1-refractory
33
wzutxsphap(ckbibclqcr) = wpywtngetx fvbjaxlyqm (jwlzckkqif, 15 - 51)
Positive
09 Jun 2023
wzutxsphap(ckbibclqcr) = wzcmqpiwpm fvbjaxlyqm (jwlzckkqif, 0 - 5.9)
Phase 1/2
34
nwsdqiqwqz(yekoqfhvhd) = npjnwvxpzb attptklxhf (hmuvsopshg, 15 - 48)
-
08 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free